Inversely, depletion of iron stocks or reduction of iron availability have been part of the treatment of PV for decades via phlebotomies; hepcidin mimetics and ferroportin inhibitors offer new therapeutic options (96). Here, SLC40A1 is linked to acquired polycythemia vera.